1.35
4.26%
-0.06
Handel nachbörslich:
1.35
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TPST?
Forum
Prognose
Aktiensplit
Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Keeping an Eye on Tempest Therapeutics Inc (TPST) After Insider Trading Activity - Knox Daily
Tempest Further Strengthens Leadership Team with - GlobeNewswire
Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs - StockTitan
Tempest Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
An Analysis of Tempest Therapeutics Inc (TPST)’s Potential Price Growth - Knox Daily
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Tempest Therapeutics Inc [TPST] Records 200-Day SMA of $3.1810 - Knox Daily
Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Is Tempest Therapeutics Inc (TPST) worth investing in despite its undervalued state? - US Post News
Scotiabank initates Tempest Therapeutics Inc (TPST) stock to a Sector outperform - Knox Daily
Anchoring Your Portfolio: Is TPST Stock a Safe Harbor? - The InvestChronicle
Ratios Uncovered: Breaking Down Tempest Therapeutics Inc (TPST)’s Trailing Twelve Months Metrics - The Dwinnex
You might want to take a look at Tempest Therapeutics Inc (TPST) now - SETE News
The Attractiveness of Investing In Tempest Therapeutics Inc (TPST) is Growing - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing Tempest Therapeutics Inc (TPST)’s Performance - The Dwinnex
How To Buy Tempest Therapeutics Inc. Stock Online in August 2024 - Traders Union
Should investors be concerned about Tempest Therapeutics Inc (TPST)? - US Post News
TPST’s 2023 Market Dance: Down -67.73% – Time to Invest? - The InvestChronicle
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Tempest Therapeutics Inc [TPST] Owner makes an insider purchase of 387,999 shares worth 0.43 million. - Knox Daily
Tempest Therapeutics appoints new VP of Quality Assurance - Investing.com
Check out these key findings about Tempest Therapeutics Inc (TPST) - SETE News
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance - GlobeNewswire
Market Momentum Report: Tempest Therapeutics Inc (TPST)’s Positive Close at 1.46 - The Dwinnex
Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance - StockTitan
Tempest Therapeutics Inc [TPST] Investment Guide: What You Need to Know - Knoxdaily.com
How should investors view Tempest Therapeutics Inc (TPST)? - US Post News
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? - MSN
Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright - Defense World
Tempest Therapeutics Inc [TPST] Shares Rise 30.25% on Thursday - Knox Daily
TPST’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Scotiabank maintains a target on Tempest Therapeutics stock By Investing.com - Investing.com Canada
Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com Canada
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? - Benzinga
Tempest stock jumps on positive FDA feedback (NASDAQ:TPST) - Seeking Alpha
Tempest Therapeutics aligns with FDA on Phase 3 cancer trial - Investing.com
Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com Australia
Tempest Therapeutics Inc (TPST) Is Worth Accumulating At Current Levels - Stocks Register
Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com India
Tempest Therapeutics aligns with FDA on Phase 3 cancer trial By Investing.com - Investing.com UK
Tempest Announces Successful End-of-Phase 2 Meeting with - GlobeNewswire
Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma - StockTitan
Its Stock Has Paid Off Big Time For Tempest Therapeutics Inc - SETE News
Scotiabank slashes price target on Tempest Therapeutics Inc [TPST] – find out why. - The DBT News
Tempest Flounders on News of Test Results - MSN
Tempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 400,000 Shares of Stock - Defense World
Tempest Therapeutics, Inc. (NASDAQ:TPST) Major Shareholder Versant Venture Capital Vi, L. Sells 387,999 Shares - Defense World
Versant entities sell Tempest Therapeutics shares worth over $967k - Investing.com
Tempest Therapeutics Inc Inc. (TPST) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Financial Health Report: Tempest Therapeutics Inc (TPST)’s Ratios Tell a Tale - The Dwinnex
Was anything negative for Tempest Therapeutics Inc (TPST) stock last session? - US Post News
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024 - MSN
TPST Stock Earnings: Tempest Therapeutics Misses EPS for Q2 2024 - InvestorPlace
A company insider recently bought 35,000 shares of Tempest Therapeutics Inc [TPST]. Should You Buy? - Knox Daily
TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - ForexTV.com
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update - wallstreet:online
Virtu Financial LLC Acquires 11,689 Shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News
TPST Stock Update: Tempest Therapeutics Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):